Compare Moderna, Inc. (MRNA) vs Prudential Financial Inc (PRU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Prudential Financial Inc — how do they compare? Moderna, Inc. trades at $136.5 (market cap $54.14B), while Prudential Financial Inc trades at $117.62 (market cap $40.57B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Prudential Financial Inc pays a 4.76% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | PRU | |
|---|---|---|
Market Cap | $54.14B | $40.57B |
Sector | Health | Financials |
52-Week High | $174.38 | $125.13 |
52-Week Low | $22.36 | $92.00 |
Enterprise Value | $50.29B | $69.35B |
Dividend Yield | — | 4.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Prudential Financial (PRU) trades at $119.38, down 2.16% today, with a neutral technical signal and bearish moving averages. The stock shows attractive valuation metrics with a P/E of 10.82 and P/S of 0.64, while recent earnings beat expectations in Q1 and Q2 2026. Revenue for 2025 was $60.97B with net income of $3.58B, and the company maintains a solid dividend of $1.40 per share. Recent news highlights participation in investor conferences and new product launches.
The outlook for PRU is mixed; fundamentals are strong with improving profitability and low valuation, but technical indicators and analyst consensus suggest caution. Risks include volatile cash flows and high debt levels. Wall Street sentiment is neutral with a consensus price target of $113.20, below the current price, indicating limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Prudential Financial Inc
Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →
